Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7T84

Structure of angiotensin II type I receptor (AT1R) nanobody antagonist AT118i4h32 G26D T57I variant

Summary for 7T84
Entry DOI10.2210/pdb7t84/pdb
DescriptorNanobody AT118i4h32 G26D T57I, CITRIC ACID, GLYCEROL, ... (6 entities in total)
Functional Keywordssingle chain antibody fragment, immune system
Biological sourcesynthetic construct
Total number of polymer chains8
Total formula weight116568.55
Authors
Nemeth, G.R.,Skiba, M.A.,Kruse, A.C. (deposition date: 2021-12-15, release date: 2022-12-07, Last modification date: 2024-10-16)
Primary citationHarvey, E.P.,Shin, J.E.,Skiba, M.A.,Nemeth, G.R.,Hurley, J.D.,Wellner, A.,Shaw, A.Y.,Miranda, V.G.,Min, J.K.,Liu, C.C.,Marks, D.S.,Kruse, A.C.
An in silico method to assess antibody fragment polyreactivity.
Nat Commun, 13:7554-7554, 2022
Cited by
PubMed Abstract: Antibodies are essential biological research tools and important therapeutic agents, but some exhibit non-specific binding to off-target proteins and other biomolecules. Such polyreactive antibodies compromise screening pipelines, lead to incorrect and irreproducible experimental results, and are generally intractable for clinical development. Here, we design a set of experiments using a diverse naïve synthetic camelid antibody fragment (nanobody) library to enable machine learning models to accurately assess polyreactivity from protein sequence (AUC > 0.8). Moreover, our models provide quantitative scoring metrics that predict the effect of amino acid substitutions on polyreactivity. We experimentally test our models' performance on three independent nanobody scaffolds, where over 90% of predicted substitutions successfully reduced polyreactivity. Importantly, the models allow us to diminish the polyreactivity of an angiotensin II type I receptor antagonist nanobody, without compromising its functional properties. We provide a companion web-server that offers a straightforward means of predicting polyreactivity and polyreactivity-reducing mutations for any given nanobody sequence.
PubMed: 36477674
DOI: 10.1038/s41467-022-35276-4
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.6 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon